A carregar...
Vulnerable COPD patients with comorbidities: the role of roflumilast
Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in February 2011 for the management of chronic obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the terms “roflumilast” and “COPD”. Reference c...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4242693/ https://ncbi.nlm.nih.gov/pubmed/25429225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S55105 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|